Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conserved residues in the Gα interface show subtype specificity in Gβγ coupling.

The Journal of biological chemistry·2026
Same author

DRUMBEAT temporally resolved interpretable machine learning model for characterizing state transitions in protein dynamics.

Communications biology·2026
Same author

Bronchial Thermoplasty Induced Changes in Blood Transcriptome Profile of Patients with Severe Asthma.

International journal of molecular sciences·2026
Same author

Socioeconomic inequalities in severe childhood asthma: results of a nationwide cohort.

ERJ open research·2026
Same author

Allostery between Distant Structural Regions Dictates Selectivity in GPCR:G Protein Coupling.

Biochemistry·2026
Same author

Conserved Residues in the Gα interface show subtype specificity in Gβγ coupling.

bioRxiv : the preprint server for biology·2026
Same journal

Norisoboldine suppresses epithelial-mesenchymal transition in colorectal cancer by simultaneously inhibiting the CXCR4/CXCR7 chemokine receptors and the JAK/STAT3 signaling pathway.

The Journal of pharmacy and pharmacology·2026
Same journal

Development, characterization, and therapeutic evaluation of uniform dezocine-loaded PLGA microspheres for sustained analgesia and cognitive protection.

The Journal of pharmacy and pharmacology·2026
Same journal

Phytochemical constituents, biological activities, toxicological profiles, and current applications of Muntingia calabura L.: an updated review.

The Journal of pharmacy and pharmacology·2026
Same journal

Uterine relaxant effects of Ageratum conyzoides essential oil: influence of hormonal status and calcium modulation.

The Journal of pharmacy and pharmacology·2026
Same journal

Liraglutide-mediated protection against ethanol-induced gastric ulcer in male and female rats: enhancement of mucosal defense, anti-inflammatory and antioxidant mechanism.

The Journal of pharmacy and pharmacology·2026
Same journal

Exploring the mechanism of action of Qufengzhitong pills in treating rheumatoid arthritis via the PI3K/AKT, NF-κB, and MAPK pathways.

The Journal of pharmacy and pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Methodological and statistical issues in pharmacogenomics.

Bas J M Peters1, Andrei S Rodin, Anthonius de Boer

  • 1Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.

The Journal of Pharmacy and Pharmacology
|May 22, 2010
PubMed
Summary
This summary is machine-generated.

Pharmacogenomics research faces challenges in clinical application despite advances. This article addresses methodological and statistical issues in study design, gene selection, and data analysis to improve reproducibility and clinical utility.

More Related Videos

Large-Scale Multi-Omics Genome-Wide Association Studies (Mo-GWAS): Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies (Mo-GWAS): Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

Related Experiment Videos

Last Updated: Jun 12, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Large-Scale Multi-Omics Genome-Wide Association Studies (Mo-GWAS): Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies (Mo-GWAS): Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Drug Development

Background:

  • Pharmacogenomics aims to personalize medicine by linking genetic variations to drug responses.
  • Despite technological progress in genotyping, widespread clinical adoption of pharmacogenomics remains limited, especially for complex diseases.
  • Existing successes include HLA-B*5701, TPMT, CYP2C9, and VKORC1 genotyping for specific drug therapies.

Purpose of the Study:

  • To identify and discuss methodological and statistical challenges in pharmacogenomic research.
  • To propose solutions for improving study design, gene/SNP selection, and data analysis.
  • To enhance the reproducibility and clinical translation of pharmacogenomic findings.

Main Methods:

  • Review of epidemiological study designs relevant to pharmacogenomics.
  • Comparison of candidate gene approaches versus genome-wide association studies (GWAS).
  • Exploration of conventional and innovative statistical methods for analyzing large pharmacogenomic datasets, addressing multiple testing and systems biology.

Main Results:

  • Lack of reproducibility is a common issue in pharmacogenomic studies, particularly observational ones involving multiple genes.
  • Specific challenges identified in study design, selection of genes and single nucleotide polymorphisms (SNPs), and data analysis.
  • Proposed analytical approaches aim to tackle issues of multiple testing and integrate systems biology concepts.

Conclusions:

  • Addressing methodological and statistical issues is crucial for advancing pharmacogenomics.
  • Improved study designs and analytical techniques are needed to increase the reliability and clinical utility of pharmacogenomic research.
  • Future research should focus on robust methodologies to bridge the gap between genetic discoveries and personalized medicine.